-
公开(公告)号：WO2018152450A1
公开(公告)日：2018-08-23
申请号：PCT/US2018/018556
申请日：2018-02-17
发明人： KIM, Dae-Shik , FANG, Frank , ENDO, Atsushi , CHOI, Hyeong-Wook , HAO, Ming-Hong , BAO, Xingfeng , HUANG, Kuan-Chun
IPC分类号： A61P31/04 , A61K31/7084 , C07F9/6527 , C07F9/6574 , C07H19/213 , A61P37/04
摘要： Provided herein are compounds useful for the treatment of cancer.
-
公开(公告)号：WO2018098305A1
公开(公告)日：2018-05-31
申请号：PCT/US2017/063047
申请日：2017-11-22
申请人： EISAI R&D MANAGEMENT CO., LTD. , BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping , MITCHELL, Lorna Helen , LARSEN, Nicholas , RIOUX, Nathalie , PRAJAPATI, Sudeep , REYNOLDS, Dominic , O'SHEA, Morgan , SAMARAKOON, Thiwanka
发明人： BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping , MITCHELL, Lorna Helen , LARSEN, Nicholas , RIOUX, Nathalie , PRAJAPATI, Sudeep , REYNOLDS, Dominic , O'SHEA, Morgan , SAMARAKOON, Thiwanka
IPC分类号： C07D403/12 , C07D401/14 , C07D231/56 , C07D401/06 , A61P35/00 , A61K31/416
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
公开(公告)号：WO2019232392A1
公开(公告)日：2019-12-05
申请号：PCT/US2019/034933
申请日：2019-05-31
申请人： EISAI R&D MANAGEMENT CO., LTD. , KIM, Dae-Shik , FANG, Frank , ENDO, Atsushi , CHOI, Hyeong-Wook , HAO, Ming-Hong , BAO, Xingfeng , HUANG, Kuan-Chun
发明人： KIM, Dae-Shik , FANG, Frank , ENDO, Atsushi , CHOI, Hyeong-Wook , HAO, Ming-Hong , BAO, Xingfeng , HUANG, Kuan-Chun
IPC分类号： A61K31/7084 , A61P35/00
摘要： Provided herein are methods for the treatment of bladder cancer.
-
公开(公告)号：WO2016164754A1
公开(公告)日：2016-10-13
申请号：PCT/US2016/026690
申请日：2016-04-08
申请人： EISAI R&D MANAGEMENT CO., LTD. , REYNOLDS, Dominic , HAO, Ming-Hong , WANG, John , PRAJAPATI, Sudeep , SATOH, Takashi , SELVARAJ, Anand
发明人： REYNOLDS, Dominic , HAO, Ming-Hong , WANG, John , PRAJAPATI, Sudeep , SATOH, Takashi , SELVARAJ, Anand
IPC分类号： C07D403/12 , A61K31/506 , A61P35/00
CPC分类号： C07D403/12
摘要： We provide FGFR inhibitors, their salts, methods of manufacture, and methods of use.
摘要翻译： 我们提供FGFR抑制剂，其盐，制造方法和使用方法。
-
公开(公告)号：WO2018152453A1
公开(公告)日：2018-08-23
申请号：PCT/US2018/018561
申请日：2018-02-17
发明人： KIM, Dae-Shik , FANG, Frank , ENDO, Atsushi , CHOI, Hyeong-Wook , HAO, Ming-Hong , BAO, Xingfeng , HUANG, Kuan-Chun
IPC分类号： A61P31/04 , A61K31/7084 , C07F9/6527 , C07F9/6574 , C07H19/213 , A61P37/04 , C07F9/6536
摘要： Provided herein are compounds useful for the treatment of cancer.
-
公开(公告)号：WO2018098251A1
公开(公告)日：2018-05-31
申请号：PCT/US2017/062978
申请日：2017-11-22
申请人： EISAI R&D MANAGEMENT CO., LTD. , BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping , MITCHELL, Lorna Helen , LARSEN, Nicholas , RIOUX, Nathalie
发明人： BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping , MITCHELL, Lorna Helen , LARSEN, Nicholas , RIOUX, Nathalie
IPC分类号： C07D209/08 , A61P35/00
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
公开(公告)号：WO2016164703A1
公开(公告)日：2016-10-13
申请号：PCT/US2016/026614
申请日：2016-04-08
申请人： EISAI R & D MANAGEMENT CO., LTD. , REYNOLDS, Dominic , HAO, Ming-Hong , WANG, John , PRAJAPATI, Sundeep , SATOH, Takashi , SELVARAJ, Anand
发明人： REYNOLDS, Dominic , HAO, Ming-Hong , WANG, John , PRAJAPATI, Sundeep , SATOH, Takashi , SELVARAJ, Anand
IPC分类号： C07D401/12
CPC分类号： C07D401/12
摘要： Methods, compounds, pharmaceutical compositions, and methods of preparing medicaments for treating hepatocellular carcinoma having an altered FGFR4 and/or FGF19 status.
摘要翻译： 方法，化合物，药物组合物和制备用于治疗具有改变的FGFR4和/或FGF19状态的肝细胞癌的药物的方法。
-
公开(公告)号：WO2016196346A1
公开(公告)日：2016-12-08
申请号：PCT/US2016/034782
申请日：2016-05-27
发明人： BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping
IPC分类号： A61K31/4439 , C07D317/02 , C07D317/06 , C07D487/04
CPC分类号： C07D231/56 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/12 , C07D471/14
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
摘要翻译： 本文公开了化合物或其药学上可接受的盐，以及通过向有需要的受试者施用治疗有效量的化合物或其药学上可接受的盐来使用该化合物治疗乳腺癌的方法。 乳腺癌可能是ER阳性乳腺癌，和/或需要治疗的受试者可以表达突变型ER-α蛋白。
-
公开(公告)号：WO2016196342A1
公开(公告)日：2016-12-08
申请号：PCT/US2016/034774
申请日：2016-05-27
发明人： HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping
IPC分类号： C07C215/46 , A61K31/133
CPC分类号： C07C255/54 , C07C237/16 , C07C2601/04 , C07D213/30 , C07D213/64 , C07D213/73
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
摘要翻译： 本文公开了化合物或其药学上可接受的盐以及使用该化合物治疗乳腺癌的方法，其通过向有需要的受试者施用治疗有效量的化合物或其药学上可接受的盐来实现。 乳腺癌可以是ER阳性乳腺癌和/或需要治疗的受试者可以表达突变型ER-α蛋白。
-
公开(公告)号：WO2016196337A1
公开(公告)日：2016-12-08
申请号：PCT/US2016/034764
申请日：2016-05-27
发明人： BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHU, Ping , ZHENG, Guo Zhu
IPC分类号： A61K31/00
CPC分类号： C07D231/56 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/12 , C07D471/14
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.028 秒)
